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ABSTRACT
EID1 (E1A-like inhibitor of differentiation 1) functions
as an inhibitor of nuclear receptor-dependent gene
transcription by directly binding to co-regulators.
Alternative targets include the co-repressor small het-
erodimer partner (SHP, NR0B2) and the co-activators
CBP/p300,indicatingthatEID1utilizesdifferentinhib-
itory strategies. Recently, EID2 was characterized as
aninhibitorofmuscle differentiation and asanantag-
onistofbothCBP/p300andHDACs.Here,wedescribe
a third family member designated EID3 that is highly
expressedintestisandshowshomologytoaregionof
EID1 implicated in binding to CBP/p300. We demon-
strate that EID3 acts as a potent inhibitor of nuclear
receptor transcriptional activity by a mechanism that
is independent of direct interactions with nuclear
receptors, including SHP. Furthermore, EID3 directly
binds to and blocks the SRC-1 interacting domain
of CBP, which has been implicated to act as the inter-
action surface for nuclear receptor co-activators.
Consistent with this idea, EID3 prevents recruitment
of CBP to a natural nuclear receptor-regulated
promoter. Our study suggests that EID-family mem-
bers EID3 and EID1 act as inhibitors of CBP/p300-
dependent transcription in a tissue-specific manner.
INTRODUCTION
CBP and p300 are highly related proteins that participate in a
variety of cellular functions (1). They serve as transcriptional
co-activators for nearly every gene-speciﬁc trans-activator,
participating in multiple regulatory networks, and commun-
icating with other co-activators and multi-protein complexes
(2). Therefore, CBP and p300 are also called co-integrators
that are involved in multiple biological processes that affect
cell growth, transformation and development. The adenoviral
transforming protein E1A is one of the most studied viral
oncoproteins. It targets both CBP and p300; the latter was
originally identiﬁed through its interaction with E1A (1). The
reprogramming activity mediated by E1A and the host cell
response to this reprogramming lead to transformation, growth
arrest or apoptosis. E1A mediates the repression of CBP/p300-
dependent trans-activation by sequestration of CBP/p300,
TBP and p/CAF (3).
Recent work has indicated the existence of cellular proteins
that share intriguing features with E1A. The ﬁrst of these
proteins, designated EID1 (E1A-like inhibitor of differenti-
ation 1), was cloned on the basis of interactions with the
retinoblastoma tumour suppressor protein and was sub-
sequently characterized as inhibitor of CBP/p300-dependent
functions on differentiation (4,5). We identiﬁed EID1 as
cofactor of the orphan nuclear receptor SHP (small heterodi-
mer partner, NR0B2) and demonstrated that EID1 inhibits
genes regulated by a variety of nuclear receptors (NRs) (6).
EID2 was cloned as the second member of this family and was
showntoactasaninhibitorofgene expression. Interestingly,it
has been suggested that EID2 inhibition is a combination of
two mechanisms, binding to CBP/p300 (7) or recruiting his-
tone deacetylases (8).
Here, we report the identiﬁcation of a third member of the
EID family. EID3 is speciﬁcally expressed in testis and, at the
sub-cellular level, localized to both nucleus and cytoplasm.
We demonstrate that EID3 inhibits gene expression mediated
by NRs, most probably by interacting with the SRC-1 inter-
acting domain (SID) of CBP that has been implicated in
co-activator assembly, thus preventing recruitment of CBP
to a natural NR-regulated promoter. Our study suggests that
interferencewithCBP/p300functionrepresentsacommonand
crucialfeatureofatleastthesetwomembersoftheEIDfamily.
MATERIALS AND METHODS
Plasmids
All human EID3 and human EID1 expression plasmids
described in this study were generated by PCR-based cloning
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length cDNAs were originally obtained by PCR from human
testis cDNA (EID3) and human breast cancer cells MCF-7
(EID1) and cloned into pGEM-T-vectors (Promega). Primers
were as follows: EID3 50-CCCCGGTAGCGAGTACGCGG-
CGAAGTAGGCGGCGGCGG-30 and 50-GTGCTTCAGTT-
TACATTTTACTCTCCATCTAACTTC-30;EI D 15 0-CGCAG-
ATCTGTCTTGCTGGAAGCTTTTTCCTAGAG-30 and 50-
CCCTCCTCAAGTAGTTTCCTCCTCTTTTAACAGCAT-30.
pSG5-derivatives were made by cloning EcoRI-fragments
from pGEM-T-EID3 or pGEM-T-EID1. pFLAG derivatives
were generated by PCR ampliﬁcation using the 50 primers
50-TTTGAATTCATGAAGATGGATGTGTCAGTGAGGGC-
CGCGGGCTGC-30 (EID3) and 50-TTTGAATTCATGTCG-
GAAATGGCT-30 (EID1) and pGEM-T vector primers, cut
with EcoRI and inserted into pcDNA-FLAG vector. The
pcDNA-FLAG vector was created using oligos encoding the
FLAG tag ligated into pcDNA3 (Invitrogen). pSG5-GAL4-
mSF-1-N1 (amino acids 98–462) was cloned by PCR using
Steroidogenic Factor-1 (SF-1) cDNA as a template into
pSG5-GAL4 using EcoRI. GAL4-mCBP C1 (9), UAS-tk-luc
(10), pCMVhGR and MMTV-luc reporter plasmid (11), pSG5-
hERa (12), 3xERE-TATA-luc (13), pSG5-mTIF2 (6), pGEX-
CBP 2058–2130 (SID) and pGEX-CBP 2058–2130 2103 K!P
(14) have been described previously.
Expression analysis of mRNA and protein
Human tissue northern blots [2 mg poly(A)
+ RNA per lane]
were sequentially hybridized with radioactively labelled
cDNA for human EID3 and b-actin (for control) according
to the manufacturer’s protocol (Clontech). The probes were
labelled using Rediprime 
II Random Prime Labelling System
(Amersham Biosciences), and thereafter puriﬁed from unin-
corporated radiolabelled nucleotides using Microspin S-200
HR columns (Amersham Pharmacia Biotech). In vitro tran-
scribed and translated proteins were produced using
[
35S]methionine (Amersham) according to the manufacturer’s
instructions (Promega). The products were then analysed by
SDS–PAGE and exposed to an X-ray ﬁlm.
Confocal microscopy and immunocytochemistry
COS-7 cells were seeded as 250 000 cells/well on cover slips
in 6-well plates and transfected as below. Cells were ﬁxed
in 3% paraformaldehyde in 5% sucrose/phosphate-buffered
saline (PBS), permeabilized with PBS/Tween-20 (0.1%)
and blocked with 5% goat serum (Jackson ImmunoResearch).
Rabbit polyclonal anti-FLAG (Sigma) were detected with
appropriate secondary antibodies conjugated to ﬂuorescein
isothiocyanate (Jackson ImmunoResearch). Nuclei were
stained using 2 mM 7-aminoactinomycin D (7-AAD) (Molecu-
lar Probes). To block nuclear export, 5 nM leptomycin B
(LMB) (Sigma) was added 5 h before ﬁxation. Sub-cellular
images were determined using a TCS SP multiband confocal
imaging system (Leica).
Mammalian cell culture and transfections
HuH7 human hepatoma cells were grown in DMEM (GIBCO,
Invitrogen Corporation) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (GIBCO, Invitrogen
Corporation) and 5% L-glutamine (GIBCO, Invitrogen
Corporation). COS-7 green monkey kidney cells were
grown in DMEM (GIBCO, Invitrogen Corporation) supple-
mented with 10% heat-inactivated FBS (GIBCO, Invitrogen
Corporation) and 5% L-glutamine (GIBCO, Invitrogen
Corporation). Cells were grown without antibiotics and
negatively tested for mycoplasma. Transient transfections
were performed using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instruction. Twenty-four
hours before transfection, 30 000 cells/well of HuH7 was
seeded in 24-well plates and for whole-cell extracts for
western blot, 250 000 cells/well were seeded in 6-well plates.
Luciferase assay—cell extracts were analysed for luciferase
activity as described previously (6).
Co-immunoprecipitations
HuH7 cells were transfected with indicated plasmids and
whole-cell extracts were prepared after 48 h post-
transfection in 50 mM Tris–HCl, pH 8.0, 150 mM NaCl,
0.5 mM EDTA, 0.5% NP-40 and 5% glycerol containing com-
plete protease inhibitor cocktail tablet (Roche). First, 100 ml
extracts were incubated for 2 h with rabbit polyclonal GAL4-
DBD antibody (sc-577; Santa Cruz Biotechnology) at 4 C
in IP-T150 buffer containing 50 mM Tris–HCl, pH. 8.0,
150 mM NaCl, 0.2% NP-40 and 5% glycerol, then 50 mlo f
a 50% mixture of protein A/G agarose (Upstate) was added
and the incubation continued overnight at +4 C. After three
washes in IP-T150 buffer, the precipitates were analysed
by SDS–PAGE followed by western blots using mouse
monoclonal anti-FLAG M5 antibody (Sigma) at a dilution
of 1:10 000.
Glutathione S-transferase (GST) pull-down assays
The GST pull-down assays were performed as described
previously (15,16). Brieﬂy, [
35S]labelled EID1, EID3 and
TIF-2 (Redivue, Amersham) were generated by in vitro trans-
lation using TNT reticulocyte lysate system (Promega). GST
fused, CBP amino acids 2058–2130, CBP amino acids 2058–
2130 2103 K!P or GST alone were expressed in BL21 (DE3)
pLys Escherichia coli cells and immobilized on glutathione
Sepharose beads (AP Biotech), following a 2 h incubation
with the [
35S]labelled proteins at 4 C, the complexes were
washed ﬁve times under stringent condition (150 mN NaCl).
Following the washing steps, the complexes were resolved by
denaturing PAGE (12% for EID3 and EID1 and 8% for TIF-2)
and autoradiographed. Wash buffer: 20 mM HEPES, pH 8.0,
150 mM NaCl, 1 mM EDTA, 0.5% Triton X and 1· protease
inhibitor cocktail (Roche). Binding buffer: wash buffer +
1.5% BSA.
Chromatin immunoprecipitation (ChIP) assays
MCF-7 cells were seeded in 150 mm dishes and grown for
3 days in phenol red-free DMEM supplemented with 5%
DCC-FCS. Ligands dissolved in dimethyl sulfoxide
(DMSO) were added for the indicated times, and protein–
DNA complexes were crosslinked with 1% formaldehyde
for 10 min. Crosslinking was quenched by adding 125 mM
glycine and cells were washed with PBS, harvested and resus-
pended in lysis buffer (50 mM Tris–HCl, pH 8.0, 150 mM
NaCl, 1 mM EDTA, 1% Triton X-100 and 0.1% sodium
deoxycholate) containing protease inhibitors (Roche,
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soluble chromatin was collected by centrifugation, and an
aliquot of the chromatin was put aside and represented the
input fraction. The supernatants were incubated with 30 ml
protein A/G Sepharose (50% slurry; Pharmacia) under gentle
agitation for 2 h at 4 C. The supernatant was transferred to a
newmicrocentrifuge tube,and0.5–1mgofantibody wasadded
and incubated overnight at 4 C. Protein A/G Sepharose (20 ml
of a 50% slurry) was then added and incubated for 1.5 h. The
pellets were successively washed for 10 min in 1 ml buffer 1
(20 mM Tris–HCl, pH 8.0, 150 mM NaCl, 2 mM EDTA, 1%
Triton X-100 and 0.1% SDS), 1 ml buffer 2 (20 mM Tris–HCl,
pH 8.0, 500 mM NaCl, 2 mM EDTA, 1% Triton X-100 and
0.1% SDS), 1 ml LiCl buffer (20 mM Tris–HCl, pH 8.0,
250 mM LiCl, 1 mM EDTA, 1% NP-40 and 1% sodium
deoxycholate) and 2· 1 ml TE (10 mM Tris–HCl, pH 8.0
and 1 mM EDTA). Protein–DNA complexes were eluted in
120 ml elution buffer (TE and 1% SDS) for 30 min, and the
crosslinks were reversed by overnight incubation at 65 C.
DNA was puriﬁed using a PCR puriﬁcation kit (Qiagen)
and eluted in 50 ml. Antibodies used were rabbit normal
IgG (Santa Cruz), anti-oestrogen receptor a (anti-ERa)
(H-184; Santa Cruz), anti-FLAG M5 (Sigma), anti-CBP
(A-22; Santa Cruz). For real-time PCR, SYBR green qPCR
supermix UDG (Invitrogen) was used with primer pairs
50-GGCCATCTCTCACTATGAATCACT-30 and 50-GGAT-
TTGCTGATAGACAGAGACGA-30 for presenilin 2 (pS2).
To calculate the enrichment differences among the receptor
and cofactors using real-time PCR, E2 treatments were
normalized to the DMSO treatments. The enrichment level
for each of the factors during DMSO treatment was set to 1
and the enrichment levels after E2 treatment of the ER
and cofactors were compared with it. Since the DMSO treat-
ment was carried out for the same amount of time as the E2
treatment, we deﬁned these as time-matched and solvent-
normalized values.
RESULTS
Cloning of a third member of the EID family
NCBI BLAST databases were searched with the EID1 open
reading frame (ORF) to identify potential functional homo-
logues and revealed the existence of several unpublished
ORFs. In this study, we focused on a predicted human
cDNA with an ORF encoding 333 amino acids, which can
be accessed through NCBI Protein Database under NCBI
accession no. AAH27612. The EID3 gene is located on
chromosome 12 (http://www.ncbi.nlm.nih.gov/genome/seq/
HsBlast.html). A mouse homologue with accession number
NM_025499 encoding 310 amino acids was also found,
located on chromosome 10 (http://www.ncbi.nlm.nih.gov/
genome/seq/MmBlast.html). Both the human and mouse
genes were located in the 50 end of the thioredoxin reductase
1 gene, in the intron between thioredoxin reductase 1 splice
variants 2 and 3. The human clone showed similarity in its
central/N-terminal part (amino acids 56–92; 73% similarity
and amino acids 106–146; 66% similarity) to the C-terminus
of EID1 (amino acids 114–147 and amino acids 148–184)
(Figure 1). Unlike EID1, EID3 has a conserved C-terminus
with unknown function referred to as COG5125 domain
(http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi). We
subsequently cloned the human full-length cDNA from testis
by PCR and designated it human EID3 as the third putative
member of the EID family.
EID3 is expressed in testis and represents a 39 kDa
intracellular shuttling protein
In order to determine the tissue distribution of EID3, multiple
tissue northern blots containing RNA from 16 different tissues
were analysed and revealed an  2.0 kb transcript highly
expressed in testis (Figure 1B). To characterize the EID3 ORF,
we produced [
35S]labelled, in vitro transcribed and translated
protein to ascertain the molecular weight. As shown in
Figure 2B, EID3 has a size of 39 kDa consistent with the
predicted molecular weight. We next studied the intracellular
localization of EID3 in comparison with EID1. FLAG-tagged
EID3 was found to be localized in the cytoplasm (66%) and in
the nucleus (34%) of transfected COS-7 cells (Figure 2A).
However, unlike EID1 (6), the intracellular distribution of
EID3 was not affected by the presence of the nuclear export
inhibitor LMB, indicating the intracellular distribution of
EID3 is regulated by mechanisms independent of CRM1-
dependent nuclear export. Further studies also show that
increasing amounts of transfected over expressed FLAG-
EID3 result in a shift in localization towards a more cytoplas-
mic and less nuclear distribution, and that it is stable according
to western blot (data not shown).
EID3 inhibits nuclear receptor-dependent
transcriptional activity
To investigate whether EID3 had inhibitory functions on tran-
scriptional activity comparable with its relatives EID1 (4–6)
and EID2 (7,8), we transiently co-transfected EID3, and for
comparison EID1, with NRs known to be expressed in testis.
SF-1 is expressed in testis and has a role in regulating the
steroid hydroxylases (17). The glucocorticoid receptor (GR)
is expressed in several cell types in testis and inhibits
steroidogenesis (18). The oestrogen receptor a (ERa)i s
expressed in testis and has a role in the expression of
oestrogen-responsive genes (19). The effects of androgens
are mediated through the androgen receptor (AR) to regulate
genes involved in primarily male sexual differentiation and
maturation, and the maintenance of spermatogenesis (20). We
observedthatEID3potently inhibited the transcriptional activ-
ity of SF-1, GR, ERa (Figure 3) and AR (data not shown).
Furthermore, we show by western blot that the expression of
the NRs is not altered by the presence of over expressed EID1
and EID3 (Figure 3). In addition, sub-cellular localization
studies suggest that FLAG-EID3 preferentially accumulates
in the cell nucleus in cells co-transfected with the NRs,
which may be due to the formation of a complex between
over expressed NR and endogenous CBP/p300 (data not
shown).
CBP-dependent transcriptional activation is
inhibited by EID3
In order to elucidate if EID3 could inhibit CBP-dependent
transcriptional activity similar to the EID1 inhibition of p300
(5), HuH7 cells were co-transfected with a plasmid containing
the GAL4 DNA-binding domain fused to the C-terminus of
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GAL4 DNA-binding sites, and a plasmid expressing wild-
type EID1 or EID3. As shown in Figure 4A, EID3 had a
profound inhibitory effect on the transcriptional activity of
CBP, indicating functional similarities to EID1. Furthermore,
western blot shows that the expression of GAL4-CBP C is not
altered by the presence of over expressed EID1 and EID3
(Figure 4B).
EID3 binds to the C-terminus of CBP in vivo and the
CBP SID in vitro
Considering that the EID1 C-terminus is homologous to an
EID3domainencompassingaminoacids106–146andthatthis
domain has been implicated in binding to the C-terminus of
CBP/p300 (4–6), we wanted to investigate whether EID3
could interact with the C-terminus of CBP in vivo. To test
for interactions of these proteins in mammalian cells, HuH7
cells were co-transfected with FLAG-EID3 and FLAG-EID1,
and GAL4-CBP C-terminus. CBP complexes were immuno-
precipitated using anti-GAL-DBD antibodies, resolved on an
SDS–PAGE gel and analysed for the presence of EID3 in the
immune-precipitates using anti-FLAG antibodies (Figure 4C).
Both EID1 and EID3 were found to be co-immunoprecipitated
with the C-terminus of CBP. GST pull-down assays showed
that both EID1 and EID3 interacted with the so-called SID of
CBP (Figure 4D), indicating a functional conservation of these
interactions within the EID family. In order to demonstrate the
Figure 1. Primary structure and expression analysis of EID3. (A) Schematic comparisons of the EID family members 1, 2 and 3, conserved domains are coloured
grey and black. (B) Tissue distribution of EID3 mRNA. Human multiple tissue northern blots were probed with radiolabelled EID3 or b-actin cDNA.
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transfection experiments were performed. These results
show that EID3 completely abolishes the TIF-2-induced trans-
activity (Figure 4E).
EID3 and EID1 blocks recruitment of CBP to the
endogenous pS2 promoter
The above results suggested that EID3 inhibits NR trans-
cription by means of interference with CBP-dependent
co-activation. To further dissect these mechanisms, we per-
formed ChIP assays using the MCF-7 breast cancer cell line,
which expresses endogenous ERa and CBP (21). Cells were
treated with 10 nM oestradiol (E2) for 1 h before harvest, and
then proteins were crosslinked to chromatin and immuno-
precipitated with antibodies against ERa, CBP or FLAG.
The ChIP analysis was performed with primers speciﬁc for
the pS2 promoter, an established oestrogen-responsive gene.
The ampliﬁed input DNA did not signiﬁcantly differ among
the samples (data not shown). The immunoprecipitated DNA
was ampliﬁed with primers that recognize the pS2 mRNA
located 2000 bp upstream of the transcriptional start site;
no amplicon was detected by real-time PCR after 45 cycles,
suggesting that the ER and CBP do not bind to that region of
the promoter (data not shown).
As shown in Figure 5, EID1 and EID3 inhibit the recruit-
ment of CBP to the pS2 promoter. However, when comparing
the occupancy of ERa at the pS2 promoter in the FLAG
transfected cells, there is an  3–4 times higher occupancy
than in the FLAG-EID1 and FLAG-EID3 transfected cells.
This may be the result of the absence of CBP owing to binding
of EID1 and EID3, which might be necessary for the proper
assembly of cofactors at the ERa-bound pS2 promoter
(21,22). There is no occupancy of EID1 and EID3 at the
pS2 promoter, indicating that they might bind to CBP before
it becomes recruited to the promoter.
DISCUSSION
In this study, we have identiﬁed EID3, a third previously
uncharacterized EID family member. The exclusive expres-
sion of EID3 in testis contrasts to the more ubiquitous expres-
sion pattern of the other two members (4–8), indicating that
EID3 might have testis-speciﬁc functions. However, unlike
EID1, EID3 has an extended C-terminal domain of unknown
function.
EID3 shows homology to a region of EID1 (Figure 1A)
that is implicated in binding to CBP/p300 (10). As shown
in Figure 4A, EID3 had a profound inhibitory effect on the
transcriptional activity of CBP, indicating functional similar-
ities to EID1 (4,5). This is most likely due to the binding of
EID3 with the C-terminus of CBP (amino acids 1678–2441)
observed in co-immunoprecipitation assays (Figure 4C),
which indicates a functional conservation of these interactions
within the EID family.
The more potent inhibition of NR transcriptional activity
mediated by EID3 compared with EID1 (Figure 3A, C and E)
could be due to the fact that a larger fraction of EID3 is
primarily located in the nucleus (Figure 2A). Furthermore,
the inhibition seems to be independent of direct interaction
of EID3 with the tested NRs, as judged from mammalian
two-hybrid interaction assays and sub-cellular co-localization
studies (data not shown). These data suggest that EID3 func-
tions as a co-inhibitor of NRs, and probably other CBP/p300-
dependent transcription factors, and thus could be involved
in the transcriptional control of testicular tissue homeostasis.
Moreover, transcriptional activation by NRs, including SF-1
(17), ER, GR (25) and AR (20), requires the action of
CBP/p300.
A sequence within the C-terminus, termed the SID,has been
mapped to amino acids 2058–2130 of CBP (26). The SID has
also been reported to interact with other nuclear factors in
addition to the p160 proteins, including IRF-3, E1A, p53,
Tax, Ets-2 and KSHV IRF-1 (27). Proteins that bind to the
SID have recently been shown to ‘share a sequence motif
similar to an amphipathic a-helix in the AD1 domain of
the p160s’ (14). Interestingly, we have localized putative
amphipathic a-helices in EID1 (amino acids 159–167) and
EID3 (amino acids 117–125) within the conserved EID
regions. Moreover, EID1 and EID3 interacts with the SID
Figure 2. Sub-cellular distribution and protein analysis of EID3. (A) Intracel-
lular localization of EID1 and EID3. FLAG-tagged EID1 and EID3 were
expressed in COS-7 cells and analysed by indirect immunofluorescence using
FLAG antibody (green) in the absence or presence of LMB (5 nM for 5 h).
Nuclei were stained with 7-aminoactinomycin D (7-AAD) (red). More than
50 cells were studied and the experiment was independently reproduced at
least three times. (B) In vitro transcribed and translated [
35S]methionine-
labelled EID1 and EID3 are shown.
Nucleic Acids Research, 2005, Vol. 33, No. 11 3565of CBP (Figure 4D) possibly via these amphipathic a-helices,
thereby competing with the p160s of the same surface. This
might disrupt an NR/co-activator complex at the promoter,
leading to a decrease in NR target gene expression as
shown in the model (Figure 6). Consistent with this idea,
we have demonstrated that EID1 and EID3 prevent recruit-
ment of CBP to a natural NR-regulated promoter using ChIP
assays (Figure 5). These results suggest that EID1 and EID3
interfere with the recruitment of CBP to the promoter-bound
ERa/co-activator complex and demonstrate a functional inter-
action between EID1 and EID3 and CBP in vivo.
We propose a model where EID1 and EID3 act as inhibitory
‘anti co-activators’ that could be critically involved in the
ﬁne-tuning of transcription, by targeting the promiscuous
co-activators CBP/p300 without interfering with the present
transcription factor.
Figure 3. Analysis of NR inhibition. HuH7 cells were grown in media containing phenol red and untreated serum. The cells were transiently transfected with
plasmids encoding EID1 or EID3 and luciferase reporter assays were performed. Western blots were performed to see whether the NR expression is not altered by
overexpressedEID1andEID3(indicatedwitharrows).(A)AluciferasereporterplasmidcontainingGAL4-DBDbindingsites,andaplasmidexpressingGAL4-SF-
1.(B)WesternblotusingGAL4-DBDantibodytodetectGAL4-SF-1andaFLAGantibodytodetectFLAG-EID1andFLAG-EID3.(C)Aluciferasereporterplasmid
containingtheMMTVpromoter,andaplasmidencodingGR,andligand(10nMdexamethasone)asindicated.(D)WesternblotusingGRantibodytodetectGRanda
FLAGantibodytodetectFLAG-EID1andFLAG-EID3.(E)AluciferasereporterplasmidcontainingtheERE,andaplasmidencodingERaandligand(10nM17-b
oestradiol) as indicated. (F) Western blot using ERa antibody to detect ERa and a FLAG antibody to detect FLAG-EID1 and FLAG-EID3.
3566 Nucleic Acids Research, 2005, Vol. 33, No. 11Figure 4. EID3 binds to the CBP SID and shows a functional interaction with the C-terminus of CBP. (A) HuH7 cells were transiently transfected with plasmids
encodingEID1orEID3,a luciferasereporterplasmidcontainingGAL4-DBDbindingsites,andaplasmidencodingGAL4-CBPC(aminoacids1678–2441).(B)A
westernblotusingGAL4andFLAGantibodiesshowthatGAL4-CBPCexpressionisnotalteredbyoverexpressedEID1andEID3.(C)Co-immunoprecipitationof
exogenous CBP (amino acids 1678–2441) and FLAG tagged EID1 or EID3. Immune complexes from HuH7 whole-cell extracts were isolated using a GAL4-DBD
antibody. Precipitates were analysed using a FLAG antibody (upper gel). The input corresponds to 20% of the material subjected to immunoprecipitation and was
detected using a GAL4-DBD antibody and a FLAG antibody. Asterisk represents unspecific band. (D) GST pull-down assay using the CBP SID fused to GST as
indicatedtogetherwith in vitro translated EID1,EID3 and TIF-2 as positivecontrol. I (input), GST-SID(CBP amino acids 2058–2130), GST-SIDmut (CBP amino
acids 2058–2130 K!P). (E) HuH7 cells were transiently transfected with plasmids encoding EID3 or TIF-2, a luciferase reporter plasmid containing GAL4-DBD
binding sites, and a plasmid encoding GAL4-CBP (amino acids 1678–2441).
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